Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

ZEJULA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Zejula, and when can generic versions of Zejula launch?

Zejula is a drug marketed by Tesaro Inc and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-six patent family members in forty-four countries.

The generic ingredient in ZEJULA is niraparib tosylate. One supplier is listed for this compound. Additional details are available on the niraparib tosylate profile page.

Summary for ZEJULA
Drug patent expirations by year for ZEJULA
Drug Prices for ZEJULA

See drug prices for ZEJULA

Generic Entry Opportunity Date for ZEJULA
Generic Entry Date for ZEJULA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEJULA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 2
Northwell HealthPhase 2
National Cancer Institute (NCI)Phase 2

See all ZEJULA clinical trials

Pharmacology for ZEJULA
Synonyms for ZEJULA
(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
0919AA
1038915-60-4
1038915-60-4 pound notMK4827 pound not MK 4827
2-[4-[(3S)-3-Piperidyl]phenyl]indazole-7-carboxamide
2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide
2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-
A3617
AC-28447
AJ-108285
AK102507
AKOS016004869
ANW-62065
AS-35248
AX8234046
BCP0726000077
BCP9000940
BDBM50316226
CHEMBL1094636
compound 56 [PMID 19873981]
CS-0780
CTK8B9123
D10140
DB-059068
DB11793
DTXSID50146129
EX-A290
FT-0770704
GTPL8275
HMC2H89N35
HY-10619
KB-03718
MK 4827
MK 4827 (Base)
MK-4827
MK-4827,(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide
MK-4827(Niraparib)
MK-4827/MK4827
MK4827
MolPort-023-219-142
NCGC00346435-01
NCGC00346435-04
Niraparib
Niraparib (USAN)
Niraparib [USAN:INN]
s2741
SB16547
SCHEMBL1421875
TC-150810
UNII-HMC2H89N35
W-5696
Zejula (TN)
ZINC43206370

US Patents and Regulatory Information for ZEJULA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tesaro Inc ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Tesaro Inc ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tesaro Inc ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ZEJULA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2109608 2018016 Norway   Start Trial PRODUCT NAME: NIRAPARIB ELLER ET; REG. NO/DATE: EU/1/17/1235 20171127
2109608 122018000048 Germany   Start Trial PRODUCT NAME: NIRAPARIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ, STEREOISOMER ODER TAUTOMER DAVON, EINSCHLIESSLICH DES TOSYLATS DAVON; REGISTRATION NO/DATE: EU/1/17/1235 20171116
2109608 CR 2018 00017 Denmark   Start Trial PRODUCT NAME: NIRAPARIB OR A PHARMACEUTICALLY ACCEPTABLE SALT, STEREOISOMER OR TAUTOMER THEREOF, PARTICULARLY THE TOSYLATE OR A HYDRATE, ESPECIALLY THE TOSYLATE MONOHYDRATE; REG. NO/DATE: EU/1/17/1235 20171120
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Merck
Boehringer Ingelheim
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.